Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

NCT05616624 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05616624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05616624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Terminated
Start date
April 5, 2023
Completion date
July 22, 2026
Enrollment
31 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, non-small cell lung cancer, small cell lung carcinoma, small-cell lung cancer